

In The Claims

1-44. (cancelled)

45. (Currently Amended) An anabolic medicament for treating a damaged tissue, ~~the tissue being characterized, when healthy, by a characteristic amino acid molar ratio for the healthy tissue per se, or for at least one peptide, polypeptide, or protein thereof,~~ the medicament comprising:

- a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,
- b) at least one polar surface active lipid; and
- c) ~~at least a plurality amino acids having an alpha carbon, the amino acids being present at a molar ratio~~ which is characteristic of healthy tissue of the type of tissue being treated for damage ~~corresponding to the characteristic amino acid molar ratio, and wherein no more than 10% of the amino acids~~ are being in dextorotary form.

46. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is synthetically produced.

47. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is obtained from a cellular or tissue source.

48. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is obtained from a cellular or tissue source.

49. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is synthetically produced.

50. (previously presented) The medicament according to claim 45, wherein at least one of said amino acids is synthetically produced.

51. (previously presented) The medicament according to claim 45, wherein said at least one of said amino acids is obtained from a cellular or tissue source.
52. (previously presented) The medicament according to claim 47, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue and organ.
53. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is selected from the group consisting of a glucosaminoglycan, a collagen, cartilage, chondroitin sulfate, a glycoprotein, and a proteoglycan.
54. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is selected from the group consisting of a phospholipid, a glycolipid, and a lipoprotein.
55. (previously presented) The medicament according to claim 45, wherein said amino acid comprises an aliphatic side chain on the alpha carbon.
56. (previously presented) The medicament according to claim 55, wherein said aliphatic side chain is a short chain fatty acid.
57. (previously presented) The medicament according to claim 56, wherein said short chain fatty acid is ammoniated.
58. (previously presented) The medicament according to claim 45, wherein said amino acid is selected from the group consisting of glycine, L-alanine, L-leucine, L-isoleucine, L-threonine, L-cysteine, L-methionine, L-serine, L-valine, and combinations thereof.

59. (currently amended) The medicament according to claim 58, comprising amino acids present at a molar ratio corresponding to a characteristic molar ratio of amino acids in cyclosporin, wherein the molar ration comprises 2 moles L-valine; 4 moles L-leucine; and 2-moles L-alanine.

60. (previously presented) The medicament according to claim 59, wherein said amino acids present at the molar ratio corresponding to the characteristic molar ratio of amino acids in cyclosporin are glycine, L-alanine, L-leucine, and L-valine.

61. (previously presented) The medicament according to claim 57, wherein said short chain fatty acid is butyric acid.

62. (previously presented) The medicament according to claim 61, wherein said amino acid is L-valine.

63. (previously presented) The medicament according to claim 61, wherein said amino acid is L-methionine.

64. (previously presented) The medicament according to claim 61, wherein said amino acid is gamma amino butyric acid.

65. (previously presented) The medicament according to claim 45, further comprising a sterile vehicle.

66. (previously presented) The medicament according to claim 48, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.

67. (previously presented) The medicament according to claim 51, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.

68. (previously presented) The medicament according to claim 49, wherein said polar surface active lipid is selected from a group consisting of a phospholipid, a glycolipid, and a lipoprotein.
69. (previously presented) The medicament according to claim 48, wherein said polar surface active lipid is selected from the group consisting of a phospholipid, a glycolipid, and lipoprotein.
70. (previously presented) The medicament according to claim 48, wherein at least one extracellular matrix compound, at least one polar surface active lipid, and at least one amino acid associate through a molecular bonding force.
71. (previously presented) The medicament according to claim 70, wherein said molecular bonding force is selected from the group consisting of electron affinity, van der Waals, and zwitterionic.
72. (previously presented) The medicament according to claim 59, wherein components of said medicament associate through a molecular bonding force.
73. (previously presented) The medicament according to claim 70, wherein said molecular bonding force is selected from the group consisting of electron affinity, van der Waals, and zwitterionic.
74. (previously presented) The medicament according to claim 45 further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

75. (previously presented) The medicament according to claim 59, further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

76. (previously presented) The medicament according to claim 48, further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

77. (previously presented) The medicament according to claim 73, further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

78-95. (cancelled)

96. (previously presented) The medicament according to claim 45 amino acid is selected from the group consisting of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, and L-valine.

97. (currently amended) The medicament according to claim 45 wherein said further comprising an amino acid is selected from the group consisting of L-alanine, L-arginine, L-asparagine, L-cysteine, L-glutamic acid, L-glutamine, L-glutamate, L-proline, L-serine, glycine, L-threonine, L-tyrosine, L-aurine, [[L-]]gamma amino butyric acid, and L-carnitine.

98. (currently amended) The medicament according to claim 45 further comprising a fatty acid selected from the group consisting of linoleic acid or and linolenic acid.

99. (previously presented) The medicament according to claim 45, wherein the acids in a ratio of four moles L-leucine: two moles L-alanine: two moles L-valine: one mole methionine: one mole L-gamma amino butyric acid: one mole [[L-]]betaine: one mole glycine.

100. (currently amended) The medicament according to claim 99, further comprising a fatty acid selected from the group consisting of linoleic acid ~~or~~ and linolenic acid.

101. (newly added) The medicament of claim 45, wherein the tissue is skin, and the molar ratio of L-amino acids is 3 moles L-methionine: 16 moles L-proline: 13 moles L-tyrosine: 30 moles L-asparagine: 8 moles L-phenylalanine: 20 moles L-cysteine: 50 moles L-leucine: 38 moles L-serine: 29 moles L-arginine: 21 moles L-threonine: 21 moles L-valine: 3 moles L-histidine: 22 moles L-alanine: 14 moles L-isoleucine: 2 moles L-tryptophan: 46 moles L-glutamic acid: 12 moles L-lysine: 14 moles L-aspartic acid: and 32 moles of L-glutamine.

102. (newly added) The medicament of claim 45, wherein the tissue is blood, and the molar ratio of L-amino acids is 15 moles L-methionine: 41 moles L-proline: 24 moles L-tyrosine: 30 moles L-asparagine: 28 moles L-phenylalanine: 13 moles L-cysteine: 51 moles L-leucine: 107 moles L-serine: 54 moles L-arginine: 59 moles L-threonine: 45 moles L-valine: 19 moles L-histidine: 37 moles L-alanine: 26 moles L-isoleucine: 19 moles L-tryptophan: 64 moles L-glutamic acid: 42 moles L-lysine: 50 moles L-aspartic acid: 30 moles L-glutamine.

103. (newly added) The medicament of claim 45, wherein the tissue is selected from the group consisting of skin, hair, nails, teeth, eye, liver, gastro-intestinal, kidney, lung, connective tissue, stem cells and HIV-damaged tissue.